Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 27;42(6):112650.
doi: 10.1016/j.celrep.2023.112650. Epub 2023 Jun 13.

METTL14 regulates chromatin bivalent domains in mouse embryonic stem cells

Affiliations
Free article

METTL14 regulates chromatin bivalent domains in mouse embryonic stem cells

Mandi Mu et al. Cell Rep. .
Free article

Erratum in

Abstract

METTL14 (methyltransferase-like 14) is an RNA-binding protein that partners with METTL3 to mediate N6-methyladenosine (m6A) methylation. Recent studies identified a function for METTL3 in heterochromatin in mouse embryonic stem cells (mESCs), but the molecular function of METTL14 on chromatin in mESCs remains unclear. Here, we show that METTL14 specifically binds and regulates bivalent domains, which are marked by trimethylation of histone H3 lysine 27 (H3K27me3) and lysine 4 (H3K4me3). Knockout of Mettl14 results in decreased H3K27me3 but increased H3K4me3 levels, leading to increased transcription. We find that bivalent domain regulation by METTL14 is independent of METTL3 or m6A modification. METTL14 enhances H3K27me3 and reduces H3K4me3 by interacting with and probably recruiting the H3K27 methyltransferase polycomb repressive complex 2 (PRC2) and H3K4 demethylase KDM5B to chromatin. Our findings identify an METTL3-independent role of METTL14 in maintaining the integrity of bivalent domains in mESCs, thus indicating a mechanism of bivalent domain regulation in mammals.

Keywords: CP: Molecular biology.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests Y.S. is a co-founder and member of the Scientific Advisory Broad of K36 Therapeutics and ABio, Inc. Y.S. is also a member of the scientific advisory board of Epicrispr Biotechnologies, Inc., and a member of the MD Anderson External Advisory Board. Y.S. holds equity in Active Motif, K36 Therapeutics, ABio, Inc., and Epicrispr Biotechnologies, Inc.

Similar articles

Cited by

Publication types

LinkOut - more resources